CD4 and glioma: Furthermore, glioma-related B7-homologue 1 (B7-H1) was identified as a strong inhibitor for activating CD4+ and CD8+ T-cell, evaluated by the increase of cytokine production, such as IFN-γ, IL-2, IL-10, and the expression of CD69, the T-cell activation marker.